Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin in Relapsed or Refractory AML
NCT00062075Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2003
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of romidepsin in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started May 2003; status: completed.
02
Drugs
romidepsin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00062075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062075.